Skip to main content

Featured article: Expression of HIF-1α and markers of angiogenesis and metabolic adaptation in molecular subtypes of breast cancer

Hypoxia makes chemo-radiation therapeutics less effective and renders the metastatic potential more favorable. Emerging research has found that the transcriptional expression of hypoxia-inducible factor-1alpha (HIF-1α) promotes the transcription of vascular endothelial growth factor A (VEGF-A) and Hexokinase-I (HK-I), which are associated to cellular growth, angiogenesis, and metastatic invasion in many malignancies. 

In the present study, Farooq and colleagues evaluated the expression of hypoxia-associated metabolic and angiogenesis markers like HIF-1α, VEGFA, and Hexokinase-I in different sub groups of breast cancers to investigate whether anti-HIF-1 could be employed as a therapeutic target to impede the role of VEGFA and HK-I in tumor development and progression in different sub-types of breast cancer.


Why publish with us

  • Home for all valid research within pre-clinical and translational medicine
  • Gold open access and compatible with growing funder mandates
  • Expert Section Editors and an international Editorial Board 
  • Free access to all content, ensuring a wide dissemination of articles
  • High article accesses with more than 117,574 full-article downloads in 2021
  • Companion journal to Journal of Translational Medicine

Aims and scope

Translational Medicine Communications is an interdisciplinary forum for all scientifically valid research from across translational medicine. We publish research that focuses on the biology of disease, as well as preclinical and basic research that is closely associated with medicine. Translational Medicine Communications will also consider reviews, methodology articles, protocols and commentaries.
Our aim is to improve transparency and reproducibility within translational medicine, which is why we consider research papers regardless of outcome or significance of findings, as well as protocols for future research. We aim to serve the translational science community by publishing all scientifically valid and technically sound articles and we are dedicated to facilitating the communication between basic and clinical science.

Translational Medicine Communications is the companion journal to Journal of Translational Medicine.

Journal of Translational Medicine considers articles focusing on information derived from human experimentation to optimise the communication between basic and clinical science.

Explore the companion journal

Editor-in-Chief: Francesco Marincola, Kite Pharma, USA

Dr. Marincola is Global Head of Research at Kite Pharma, Santa Monica, California. He was previously President and Chief Scientific Officer at Refuge Biotechnologies, Menlo Park, California, Distinguished Research Fellow at AbbVie Corporation; Chief Research Officer at Sidra Research, Qatar; and Tenured Investigator at the National Institutes of Health, Maryland. Dr. Marincola founded in 2003 the Journal of Translational Medicine and is the Editor-in-Chief. He is also Editor-in-Chief of Translational Medicine Communications. He is past-president of the Society for the Immunotherapy of Cancer (SITC) and the International Society for Translational Medicine. He edited several books including the SITC-affiliated Cancer Immunotherapy Principles and Practice Textbook. Dr. Marincola is also an award winning fiction author of The Wise Men of Pizzo and Cat Behind the Window.

Annual Journal Metrics

  • Speed 2023
    Submission to first editorial decision (median days): 9
    Submission to acceptance (median days): 75

    Usage 2023
    Downloads: 221,911
    Altmetric mentions: 163